Gain Therapeutics Statistics
Total Valuation
GANX has a market cap or net worth of $49.46 million. The enterprise value is $40.76 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, before market open.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GANX has 27.79 million shares outstanding. The number of shares has increased by 75.99% in one year.
| Current Share Class | 27.79M |
| Shares Outstanding | 27.79M |
| Shares Change (YoY) | +75.99% |
| Shares Change (QoQ) | +3.54% |
| Owned by Insiders (%) | 4.82% |
| Owned by Institutions (%) | 8.94% |
| Float | 26.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 526.45 |
| PB Ratio | 8.93 |
| P/TBV Ratio | 8.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.22, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.22 |
| Quick Ratio | 1.85 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -290.21% and return on invested capital (ROIC) is -159.80%.
| Return on Equity (ROE) | -290.21% |
| Return on Assets (ROA) | -97.09% |
| Return on Invested Capital (ROIC) | -159.80% |
| Return on Capital Employed (ROCE) | -308.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$837,082 |
| Employee Count | 25 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GANX has paid $617,450 in taxes.
| Income Tax | 617,450 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.21% in the last 52 weeks. The beta is 0.17, so GANX's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -25.21% |
| 50-Day Moving Average | 1.90 |
| 200-Day Moving Average | 1.93 |
| Relative Strength Index (RSI) | 43.53 |
| Average Volume (20 Days) | 226,176 |
Short Selling Information
The latest short interest is 290,186, so 1.04% of the outstanding shares have been sold short.
| Short Interest | 290,186 |
| Short Previous Month | 295,777 |
| Short % of Shares Out | 1.04% |
| Short % of Float | 1.10% |
| Short Ratio (days to cover) | 0.97 |
Income Statement
| Revenue | n/a |
| Gross Profit | -10.65M |
| Operating Income | -20.35M |
| Pretax Income | -21.54M |
| Net Income | -20.93M |
| EBITDA | -20.31M |
| EBIT | -20.35M |
| Earnings Per Share (EPS) | -$0.82 |
Full Income StatementBalance Sheet
The company has $9.07 million in cash and $606,860 in debt, giving a net cash position of $8.46 million or $0.30 per share.
| Cash & Cash Equivalents | 9.07M |
| Total Debt | 606,860 |
| Net Cash | 8.46M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 5.78M |
| Book Value Per Share | 0.20 |
| Working Capital | 6.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$19.11 million and capital expenditures -$22,493, giving a free cash flow of -$19.13 million.
| Operating Cash Flow | -19.11M |
| Capital Expenditures | -22,493 |
| Free Cash Flow | -19.13M |
| FCF Per Share | -$0.69 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |